🇪🇺EU · EMAWithdrawn from rolling reviewATC: J07BX03

CureVac’s COVID-19 vaccine (CVnCoV)(single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2)

Marketing Authorisation Holder: CureVac AG

INN: COVID-19 mRNA vaccine

Indication

COVID-19 Vaccine

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about CureVac’s COVID-19 vaccine (CVnCoV) — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about CureVac’s COVID-19 vaccine (CVnCoV)Create Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.